Dr. Ancell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-322-3000Fax+1 615-936-0605
Education & Training
- Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
- Vanderbilt University Medical CenterResidency, Internal Medicine, 2005 - 2008
- University of Missouri-Columbia School of MedicineClass of 2005
Certifications & Licensure
- TN State Medical License 2007 - 2025
- AL State Medical License 2020 - 2020
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 11 citationsThe Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outc...Yu-Wei Chen, Matthew D Tucker, Landon C Brown, Hesham A Yasin, Kristin K Ancell
Cancers. 2022-08-07 - 24 citationsAssociation of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman
Biomarker Research. 2021-11-03 - 10 citationsBlood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage DiseaseWade T. Iams, Prasad R. Kopparapu, Yingjun Yan, Anel Muterspaugh, Zhiguo Zhao
JTO Clinical and Research Reports. 2020-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: